论文部分内容阅读
目的探讨腹腔镜手术联合促性腺激素释放激素动剂(gonadotrophin releasing hormene agenist GnRH-a)治疗子宫内膜异位症(endometriosis,EMS)患者临床效果。方法选取2015年3月—2016年1月本院收治的EMS患者共62例,将入选患者随机分为试验组和对照组各31例。其中试验组患者行腹腔镜手术联合GnRH-a进行治疗,对照组患者行腹腔镜手术联合孕三烯酮进行治疗,对比观察治疗后两组患者各项相关指标变化情况。计量资料比较采用t检验,计数资料比较采用χ~2检验,P<0.05为差异有统计学意义。结果试验组患者的总有效率为96.8%,显著高于对照组的74.2%,差异有统计学意义(P<0.05)。治疗6个月两组患者的FSH、LH、E_2[(2.3±1.2)、(2.4±0.9)U/L、(97.6±22.7)ng/L与(3.9±1.3)、(3.8±1.3)U/L、(153.8±23.4)ng/L]比较,差异均有统计学意义(均P<0.05)。两组患者症状缓解率、妊娠率、复发率比较,差异均有统计学意义(均P<0.05)。结论腹腔镜手术联合GnRH-a治疗EMS患者可有效改善患者生殖激素水平,减少复发率,效果显著,值得于临床中进一步推广使用。
Objective To investigate the clinical effect of laparoscopic surgery combined with gonadotrophin releasing hormene agenist (GnRH-a) in the treatment of patients with endometriosis (EMS). Methods A total of 62 EMS patients admitted to our hospital from March 2015 to January 2016 were randomly divided into experimental group (31 cases) and control group (31 cases). The patients in the experimental group were treated with laparoscopic surgery combined with GnRH-a, and the control group were treated with laparoscopic combined with gestrinone. The changes of the relevant indicators in both groups were observed and compared. Measurement data were compared using t test, count data were compared using χ ~ 2 test, P <0.05 for the difference was statistically significant. Results The total effective rate of the experimental group was 96.8%, significantly higher than 74.2% of the control group, the difference was statistically significant (P <0.05). The FSH, LH, E_2 (2.3 ± 1.2), (2.4 ± 0.9) U / L, (97.6 ± 22.7) ng / L and (3.9 ± 1.3) and (3.8 ± 1.3) U /L,(153.8 ± 23.4)ng/L], the differences were statistically significant (P <0.05). Two groups of patients with symptom relief rate, pregnancy rate, recurrence rate, the difference was statistically significant (P <0.05). Conclusion Laparoscopic surgery combined with GnRH-a in the treatment of EMS patients can effectively improve the level of reproductive hormone in patients with reduced recurrence rate, the effect is significant, it is worth further promotion in clinical use.